We investigated the expression of neuronal nitric oxide synthase (nNOS) in a rat retina model of chronic glaucoma, which was produced by electrocauterization of the episcleral vessels. Western-blot analysis showed that nNOS expression was significantly increased in cauterized retinas. nNOS immunoreactivity was observed in the cells of both the inner nuclear layer and the ganglion cell layer. Double labeling of retinal ganglion cells (RGCs) revealed that RGCs in the retina of cauterized rat was nNOS-immunopositive. Systemic administration of L-NAME (N G -nitro-L-arginine-methyl-ester), a non-specific NOS inhibitor, reduced RGC loss in cauterized rat retina, but there was no statistical significance (P = .06). These results suggest that the cytotoxicity of excessive NO plays a role in selective RGC loss in glaucoma.
Introduction
Glaucoma is a major cause of irreversible blindness worldwide. In glaucoma, the most distinctive pathologic change is the selective loss of retinal ganglion cells (RGCs) (Morgan, 2002 ) via a mechanism involving the apoptosis pathway (Quigley et al., 1995) . The mechanism of RGC loss in glaucoma is not fully understood, but the depletion of neurotrophic factors by blockage of axoplasmic flow through direct compression, ischemia, and inflammatory processes, glutamate excitotoxicity, and reactive oxygen, have been proposed as possible mechanisms (Ko, Hu, Ritch, & Sharma, 2000; Quigley et al., 2000) .
Nitric oxide (NO), a free radical with a half-life of a few seconds, plays various physiological and pathological roles in the nervous system . NO is synthesized from its precursor, L-arginine, by the enzyme NO synthase (NOS) (Palmer, Ashton, & Moncada, 1988) . Three major isoforms of NOS have been identified: neuronal (nNOS), endothelial (eNOS), and inducible (iNOS) . The neuronal and endothelial NOS isoforms are constitutively expressed and are calcium-and calmodulin-dependent, whereas iNOS is calcium-independent and is induced by endotoxin and cytokines (Kuo & Schroeder, 1995; Moncada, Palmer, & Higgs, 1991; Nathan & Xie, 1994) .
NO has been implicated as a neurotoxin that plays a role in various neurodegenerative diseases of the central nervous system. Animal models of human neurodegenerative diseases have implicated NO in stroke (Malinski, Bailey, Zhang, & Chopp, 1993) , multiple sclerosis (Bo et al., 1994) , and Parkinson's disease (Hunot et al., 1996) . In the glaucomatous optic nerve head, excessive NO may be responsible, at least in part, for degeneration of axons of retinal ganglion cells. Induction and up-regulation of iNOS has been found in astrocytes in the prelaminar and lamina cribrosa of optic nerve heads of glaucoma patients (Liu & Neufeld, 2000; Neufeld, Hernandez, & Gonzalez, 1997) , and inhibition of NOS delays axonal degeneration and 0042-6989/$ -see front matter Ó 2007 Elsevier Ltd. All rights reserved. doi:10.1016/j.visres.2007.07. 011 promotes the survival of axotomized RGCs (Koeberle & Ball, 1999) . The pharmacologic use of aminoguanidine, an iNOS inhibitor, significantly inhibits the loss of RGCs in an experimental rat model of chronic ocular hypertension (Neufeld, 2004; Neufeld, Sawada, & Becker, 1999) .
Although most studies of the role of NOS in glaucoma have focused on iNOS, a change in nNOS expression associated with glutamate excitotoxicity may be a mechanism of RGC loss in glaucoma. In many glutaminergic junctions, NO is the post-junctional, intracellular mediator for glutamate released into the synapse. Although glutamate neurotoxicity in primary neuronal cell culture is mediated, at least in part, by excess NO (Dawson, Dawson, Bartley, Uhl, & Snyder, 1993; Dawson, Dawson, London, Bredt, & Snyder, 1991) , the role of nNOS in glaucomatous degeneration is not fully understood. Therefore, in the present study, we investigated the possible role of NO in the glaucomatous loss of RGCs by examining retinal nNOS expression in a rat model of chronic glaucoma. In particular, we determined the localization of nNOS-immunoreactive cells based on the selective loss of RGCs.
Materials and methods

Rat glaucoma model
Forty-eight adult male Sprague-Dawley rats weighing 200-250 g were used in this study. At 1 and 6 weeks after cauterization, six eyes in each experimental group were used for Western-blot and immunohistochemical analysis of nNOS expression, and at 4 weeks after cauterization, six eyes in each group were used for counting RGCs marked by retrograde labeling. All animals were treated in accordance with the ARVO Statement for Use of Animals in Ophthalmic and Vision Research. The Animal Care Committee of the College of Medicine of The Catholic University of Korea approved the animal protocols and monitored animal use. Animals were housed with a 14-h light/10-h dark cycle with standard food and water provided ad libitum.
Elevated intraocular pressure (IOP) was induced in one eye of animals by cauterizing the three episcleral veins as follows. Rats were anesthetized with an intraperitoneal (i.p.) injection of 4% chloral hydrate (Merck, NJ, USA; 400 mg/kg). After conjunctival incision, extraocular muscles were isolated, and the four major limbal draining veins were identified based on location, relative immobility, larger diameter, and branching pattern. Three of the episcleral veins were cauterized using a cautery (Bovie Company, FL, USA) and a surgical microscope (Olympus, Tokyo, Japan) as previously described (Shareef, Garcia-Valenzuela, Salierno, Walsh, & Sharma, 1995) . Normal perfusion of the retina after cauterization was confirmed by planar ophthalmoscopy. Only those eyes that did not suffer scleral burns with subsequent necrosis or any complications from surgery were used for subsequent analysis.
IOP was measured using a tonometer (Tono-Pen; Solan, Florida, USA) after topical anesthesia with 0.5% Alcaine eye drops (Alcon Inc., Fort Worth, TX). Nine readings were taken and averaged. Animals were kept as calm as possible to minimize effects on the IOP readings. The average IOP was measured in rats at baseline (prior to cauterization) and at 1, 3, 7, 10, 14, 21, 35 , and 42 days post-cauterization.
Retrograde labeling and counting of RGCs
We conducted retrograde RGC labeling by the stereotaxic addition of two different dyes, Fluoro-gold (FG, Fluorochrome, USA) or 4-Di-10-ASP (DiA, Molecular Probes, Eugene, USA). We found that FG was the best dye for identifying RGCs or retrograde axoplasmic flow disturbance and for quantitative analysis, but it was inadequate for double staining of RGCs. DiA stained RGCs well and performed better in double staining.
Briefly, after fixing the head of anesthetized rats in a stereotaxic apparatus (Stoelting, Wood Dale, IL) with the skull held horizontally, FG and DiA tracer was applied into the superior colliculus using these coordinates: 6 mm posterior to the rat bregma, 1.2 mm lateral to the midline, and 3.8-4.2 mm depth from the top of the skull. These tracers are taken up by the axon terminals of the RGCs in the superior colliculus and transported in a retrograde manner to the retinal somas. Eyes were enucleated 4-5 days after injection of FG and DiA, and the retinas were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 (PB), for 30 min. Each retina was then isolated as flatted wholemounts by four radial incisions, and mounted on slides with the vitreal side facing up.
Retinal wholemounts were examined and photographed with a fluorescence microscope (Axiophot, Zeiss, Oberkochen, Germany). RGC counting was performed as described previously (Levkovitch-Verbin et al., 2003) . Each retinal quadrant was divided into central, middle, and peripheral locations (1, 2, and 3 mm from the optic disc, respectively), and then the number of RGCs in each of the six fields (one central field, two middle fields, and three peripheral fields) of each quadrant were counted. Corresponding regions from each retina of the normal and cauterized groups were compared. A labeled RGC was counted if the entire cell or the nucleus of the cell was visible within the micrograph. To minimize variability, RGC counting was performed in a masked fashion by the same investigator.
Western-blot analysis
The retinas were homogenized in RIPA buffer (0.5 M Tris-HCl, pH 7.5, 1% Triton X-100, 5% SDS, 5% deoxycholic acid, 10% glycerol, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 5 lg/ml aprotinin, 1 lg/ml leupeptin, 1 lg/ml pepstatin, 200 mM sodium orthovanadate, 200 mM sodium fluoride). Tissue extracts were incubated for 10 min on ice and then clarified by centrifugation at 10,000g for 25 min at 4°C. Total protein in the retinal extracts was determined using a standard bicinchoninic acid (BCA) assay (Pierce, Rockford, IL).
Retinal extracts (30 lg total protein) were resuspended in 5· sample buffer (60 mM Tris-HCl (pH 7.4), 25% glycerol, 2% SDS, 14.4 mM 2-mercaptoethanol, and 0.1% bromophenol blue) at a 4:1 ratio, boiled for 5 min, and resolved by SDS-PAGE. The separated proteins were then transferred to a nitrocellulose membrane (Hybond-C; Amersham Pharmacia Biotech, Freiburg, Germany). The membranes were washed and blocked for 45 min with 5% skimmed milk powder in TBST buffer (20 mM Tris-HCl, pH 7.6, 137 mM NaCl, 0.1% Tween 20). The blots were then incubated for 15 h at 4°C with antibodies against nNOS (Sigma, CA, USA), iNOS (Upstate, CA, USA) or eNOS (Transduction Laboratory, CA, USA) that were diluted 1:1000 in the blocking solution. The membrane was rinsed by three 10 min washes with TBST and then incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody (1:10,000) for 1 h at room temperature. Bound antibodies were detected using an enhanced chemiluminescence system (ECL; Amersham, Piscataway, NJ) and X-ray film, and the signal intensity was measured using an ImageMasterÒVDS system (Pharmacia Biotech, San Francisco, CA). Immunoblot experiments were performed three times for each retina and then quantified as the mean value.
Immunohistochemistry
At the end of each experimental period, eyes were enucleated and dissected, and the posterior eyecups were placed in chilled fixative (4% paraformaldehyde in PB). Isolated retinas were divided into small pieces and immersion-fixed in the same fixative for 2 h at 4°C. After several washes, the fixed retinas were cryoprotected in PB containing 30% sucrose for 6 h at 4°C and stored at À70°C. Samples for vibratome sectioning were preembedded in 3% agar in deionized water. Vibratome sections (50 lm) were collected and washed several times in phosphate-buffered saline, pH 7.4 (PBS). The sections were incubated in 10% normal donkey serum in PBS for 1 h at room temperature and then incubated with a rabbit polyclonal antibody against nNOS (1:7000; Sigma) in PBS overnight at 4°C.
For nNOS immunohistochemistry, sections were washed the next day several times with PBS and then incubated in HRP-conjugated donkey anti-rabbit IgG antibody (1:1000; Jackson Immuno-Research Laboratories, West Grove, PA, USA) for 2 h at room temperature. The sections were washed several times in 0.05 M Tris-HCl buffer, pH 7.4 (TB) for 10 min each, and the immune reaction was visualized by incubation in TB containing 0.05% 3,3 0 -diaminobenzidine tetrahydrochloride (DAB; Sigma) and 0.01% H 2 O 2 for 1 min. Sections were observed and photographed with an Olympus light microscope. For quantitative analysis of the number of nNOS-positive cells, the cell bodies were counted in the ganglion cell layer (GCL) and inner nuclear layer (INL) under the microscope at the magnification of 200·. Each field was outlined with an ocular graticule, measuring 0.0144 mm 2 (0.48 mm width · 0.03 mm height), (n = 6 per control and 6 weeks after cauterization, three sections for each eye). Statistical analysis was performed using Student's t-test as described in quantification and statistics. Double labeling for nNOS was performed the next day after several washes with PBS. Sections were incubated with goat anti-rabbit fluorophore-conjugated secondary antibody (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), washed, cover-slipped, and examined by confocal laser-scanning microscopy (Bio-Rad Laboratories, Hercules, CA, USA).
Inhibition of NOS using
, a non-specific NOS inhibitor, was administered i.p. at 40 mg/kg one day after cauterization. The L-NAME was dissolved in PBS and injected once daily for 4 weeks (n = 6). Four weeks after L-NAME administration, the eyes were enucleated and examined for the extent of RGC loss. The control animals received i.p. injections of the PBS vehicle for 4 weeks.
Quantification and statistical analysis
All data are expressed as means ± SD. Comparisons between two groups were performed using Student's t-tests and paired t-tests. Comparisons among multiple groups were performed using one-way analysis of variance (ANOVA) with Duncan's multiple pair-wise comparison tests. Differences were considered significant at P < .05.
Results
Elevation of intraocular pressure (IOP)
The IOP was 17.75 ± 1.29 mm Hg in normal control eyes, but in the experimental group (n = 24), it had increased to 30 mm Hg at one day post-cauterization (30.5 ± 2.0 mm Hg). The IOP in the experimental group remained elevated over the entire 6-week experimental period, with an average of 32.1 ± 0.9 mm Hg (P < .05) (Fig. 1). 
Expression of NOS isoforms
Western-blot analysis was used to quantify levels of NOS isoforms in normal and cauterized rat retinas. Densitometric analysis revealed that nNOS expression was significantly higher in cauterized eyes than in normal eyes, and that this elevated nNOS expression in cauterized eyes was sustained throughout the experimental period. The expression of iNOS was increased significantly at 1-week post-cauterization but did not change thereafter, and no significant changes in eNOS expression were observed (Fig. 2) .
nNOS immunoreactivity
In the normal retinas, nNOS immunoreactivity was observed in cells of the ganglion cell layer (GCL) and inner nuclear cell layer (INL) (Fig. 3a and b) . Based on their morphologies and locations, the immunoreactive cells in the INL were thought to be amacrine cells (arrowheads) and bipolar cells (open arrows) (Fig. 3) . In cauterized rat retinas, the distribution of nNOS immunoreactivity 6 weeks after cauterization was the same as that of the normal retina. However, the intensity of the signal and the number of immunopositive cells were higher than those of the normal retina ( Fig. 3c and d) . In the quantitative analysis, cells with nNOS immunoreactivity in the GCL and INL were significantly increased, compared with those of control retinas. The INL was numerically superior to GCL in the distribution of nNOS immunoreactive cells in both groups (Table 1) .
Expression of nNOS in the ganglion cell layer
We examined whether the RGCs themselves expressed nNOS using immunohistochemistry with retrograde labeling of RGCs with DiA ( Fig. 4a and d) . We confirmed that the INL and GCL exhibited nNOS immunoreactivity in normal rat retinas (Fig. 4b) . The number of nNOS-positive cells in the GCL increased after cauterization (Fig. 4e) . At A chronic glaucoma rat model was prepared as described in Section 2, and the IOPs of control (d) and cauterized (s) eyes were measured at the indicated times postcauterization. The experimental group exhibited a significant and sustained increase in IOP during the experimental period; the IOP was elevated to 30.5 ± 2.0 mm Hg one day after cauterization, and it remained at this level throughout the 6-week follow-up period (32.1 ± 0.9 mm Hg, P < .05). Error bars = SD. * P < .05, compared to the control.
6 weeks post-cauterization, some nNOS-positive cells localized in the GCL were identified as RGCs by their overlapping fluorescence after retrograde labeling of ganglion cells (Fig. 4f, arrows) . However, in normal rat retinas, such overlapping of fluorescence was not observed, indicating that the nNOS-positive cells in the GCL of non-cauterized Fig. 2 . Expression of three NOS isoforms in the retina of the chronic glaucoma model. Proteins were extracted from retinas of control and experimental rats at 0, 1, and 6 weeks post-cauterization. Expression levels of nNOS, iNOS, and eNOS proteins were determined by immunoblot analysis (a) and the relative intensity of NOS isoforms from immunoblots was measured by densitometric analysis (b). Error bars = SD. * P < .05, compared to the control; P < .05, compared to 1-week post-cauterization. retinas were predominantly displaced amacrine cells (Fig. 4c) .
Effect of L-NAME on ganglion cell protection in chronic glaucoma
We next examined the effect of administration of L-NAME, a non-specific NOS inhibitor, on the IOP and on RGC loss after cauterization. In the absence of L-NAME treatment, cauterization increased the average IOP from 17 to 32 mm Hg, and L-NAME treatment did not alter this response. At 4 weeks post-cauterization, both the L-NAME-treated and non-treated rats had similar IOP (Fig. 5) . We examined the RGC-protective effects of L-NAME by counting the number of RGCs after retrograde transport of FG into the ganglion cells. After 4 weeks of elevated IOP, retinas from L-NAME-treated and non-treated rats had 107,716 ± 2833 and 101,646 ± 2944 ganglion cells, respectively, statistically less than in non-cauterized rat retinas (P < .05). L-NAME was found to inhibit RGC loss in the chronic glaucoma rat model. But this inhibition was not statistically significant (P = .0618) when assessed by a two-tailed t-test. (Fig. 6) 
Discussion
Glaucoma is characterized by progressive cupping of the optic nerve head, selective loss of RGCs, and loss of visual field. Elevated IOP is considered a primary risk factor for the initiation and progression of glaucomatous optic neuropathy. Table 1 The average number of nNOS-positive cell count (per 0.0144 mm 2 retinal area) in the GCL and INL after chronic ocular hypertension injury Normal Cauterization GCL 1.1 ± 0.4 3.4 ± 0.9 * INL 3.8 ± 0.9 7.7 ± 0.8 * Values are expressed as means ± SD. Statistical significance was evaluated by Student's t-test (n = 6 per control and week 6, three sections for each eye). Cauterization, 6 weeks post-cauterization; GCL, ganglion cell layer; INL, inner nuclear layer. * P < .05 compared to the control retina. 5 . Effect of L-NAME on IOP. L-NAME (40 mg/kg) was injected into the peritoneum of normal and chronic glaucoma model rats every day for 4 weeks, and their IOPs were measured. After cauterization, the average IOP was higher than that of control eyes, and L-NAME had no effect on this increase, which was similar to that observed in the non-treatment group. * P < .05, compared to the control.
NO has been shown to be involved in various neurodegenerative disorders. In the neural retina, it plays an important role in regulating phototransduction, modulating output at photoreceptor synapses, and controlling ganglion cell excitability (Ahmad et al., 1994; Cudeiro & Rivadulla, 1999; Savchenko, Barnes, & Kramer, 1997; Shiells & Falk, 1992) . Recently, NO and NOSs have been studied in connection with the loss of RGCs via the apoptosis pathway in glaucoma, but a direct link between retinal NO activity and IOP elevation has yet to be established. Most studies of the role of NOS in glaucoma have focused on iNOS. iNOSpositive cells are not detected in normal tissue, but are sparsely present in glaucomatous optic nerve heads. Immunohistochemistry data suggest that these cells are reactive astrocytes and microglia. Neufeld et al. hypothesized that the excessive NO produced by astrocytes plays a major neurodestructive role in the chronic degeneration of axons in the optic nerve head that is characteristic of glaucoma (Liu & Neufeld, 2000; Neufeld et al., 1997) . However, nNOS has not been a matter of concern in a glaucoma models. Recently, increased expression of nNOS in the retina and optic nerve head was reported in rats with elevated IOP (Vidal et al., 2006) .
We hypothesized that neuronal NO might be a mediator of RGC death in glaucoma based on several observations: (i) glaucoma is characterized by selective ganglion cell loss, (ii) elevated glutamate concentration has been observed in the vitreous of primary open-angle glaucoma patients, and (iii) in many glutaminergic junctions, the post-junctional, intracellular mediator for glutamate is NO produced by nNOS.
An experimental rat model of chronic glaucoma produced by the electrocauterization of episcleral vessels (Shareef et al., 1995) is similar to human glaucoma and is frequently used for glaucoma studies. In this model, a decrease in the outflow of aqueous humor causes sustained elevation of the IOP, resulting in chronic damage to the neuroretina. In addition, ischemia is prevented because the elevated IOP does not exceed systolic blood pressure and less variation between individuals is observed (Urcola, Fig. 6 . Neuroprotective effect of L-NAME on loss of RGCs in the chronic glaucoma rat model. Chronic glaucoma rats received daily injections with L-NAME (40 mg/kg). Ganglion cells were labeled with FG by retrograde transport in the L-NAME-treated and non-treated rats (a). At 4 weeks postcauterization, the increased IOP reduced the number of RGCs by $35%. This reduction was ameliorated by L-NAME treatment (b), but the statistical significance of the effect was marginal, as assessed by a two-tailed t-test (P = .0618). Hernandez, & Vecino, 2006) . Therefore, in the present study we used a glaucoma rat model in which three episcleral vessels were cauterized. This treatment resulted in a consistent, 1.7-fold increase in IOP during the 6 weeks after cauterization. Pang et al. investigated the involvement of iNOS, but not nNOS, in experimental glaucoma model using episcleral injection of hypertonic saline and concluded that glaucomatous optic neuropathy was not associated with a significant change in iNOS expression in the retina, which was not consistent with the previously published results from Neufeld et al. (Neufeld et al., 1999; Pang et al., 2005) . They pointed out technical differences in the elevation of IOP to explain the discrepancy and presumed that cauterization of episcleral vessels might provide localized ocular ischemia and ocular congestion. We cannot exclude the possibility of choroidal circulation disturbance in our glaucoma model, but there is not definite evidence to support this histologically. Besides, based on choroidal circulation disturbance alone, it is hard to explain the various changes in inner retina observed in our experiments using episcleral vein cauterization.
Findings of nNOS activity in the retina have been reported previously, but the particular cell type involved has not been clearly identified. Total NO levels increased twofold in the retina of an experimental glaucoma model (Siu et al., 2002) . Although nNOS immunoreactivity has been associated with amacrine cells in the INL, displaced amacrine cells in the GCL, and sometimes RGCs, the localization of nNOS immunoreactivity to RGCs has not been a consistent finding of published studies. Neufeld et al. reported localization of nNOS to photoreceptors, amacrine cells, and RGCs in normal rat and human retinas (Neufeld, Shareef, & Pena, 2000) . However, optic nerve transection induces widespread expression of nNOS immunoreactivity in rat RGCs that normally do not express this enzyme activity, suggesting that axotomized ganglion cells degenerate via NO-mediated excitotoxicity (Lee et al., 2003) .
This study demonstrated a significant increase in expression of nNOS in the retina of a chronic glaucoma model. Levels of nNOS protein also increased significantly over time. Because the most distinctive pathologic change in glaucoma is the loss of RGCs, we labeled RGCs using stereotactic surgery to distinguish them from displaced amacrine cells and then observed the localization of the nNOS-immunoreactive cells. Our data demonstrate that chronically elevated IOP increases the expression of nNOS immunoreactivity both in RGCs that normally do not express this enzyme activity and in amacrine cells that normally express this enzyme activity in some degrees.
Although the mechanism by which chronically increased IOP induces an increase in nNOS expression in the retina is unknown, glutamate excitotoxicity may be involved. Glutamate is the principal excitatory neurotransmitter in the CNS and the retina and has been found to be increased in glaucoma (Dreyer, Zurakowski, Schumer, Podos, & Lipton, 1996) . RGCs damaged by direct compression, ischemia, and inflammatory processes produce excess glutamate, and the glutamate stimulates RGCs by binding to their N-methyl-D-aspartic acid (NMDA) receptors. This interaction leads to a large influx of Ca 2+ , which causes inappropriate activation of complex cascades of nucleases, protease, and lipases, resulting in cell death (Hollmann & Heinemann, 1994; Yang, 2004) . A Ca 2+ /calmodulin-dependent NOS isozyme is among these activated enzymes.
Pharmacological inhibition of NOS activity has been investigated for its possible neuroprotective effect in glaucoma. In a rat glaucoma model, pharmacological use of aminoguanidine, an inhibitor of NOS-2, significantly reduces the loss of RGCs (Neufeld, 2004; Neufeld et al., 1999) . In a rat model of IOP-induced ischemia, systemic treatment with antagonists of the NMDA and non-NMDA subtypes of glutamate receptors prevents RGC death, and a similar neuroprotective effect is produced by systemic treatment with L-NAME (Nucci et al., 2005) .
L-NAME (N G -nitro-L-arginine-methyl-ester) is a competitive inhibitor of the enzyme NOS. So, in this study, the neuroprotective effects of L-NAME on retinas subjected to chronically elevated IOP were confirmed by determining numbers of RGCs, not the level of NOS expression. We observed that L-NAME caused a reduction in the RGC loss induced by chronically elevated IOP; however, this effect was not statistically significant, when assessed by a two-tailed t-test (P = .0618). This result may reflect a limited role for NO in RGC loss in the glaucoma model, or it may be an artifact (a type-II error) of the relatively small sample size (n = 6 rats per group). L-NAME could affect nNOS expression in the retina, as well as iNOS expression in the optic nerve head, but an increase in iNOS was not observed in our animal glaucoma model.
In our study, L-NAME did not decrease IOP. This finding conflicts with those of some other studies concerning L-NAME and IOP. For example, systemic (1-100 mg/kg) and topical (0.5% or 1%) administration of L-NAME was reported to prevent IOP increase in an animal model of glaucoma (Giuffrida, Bucolo, & Drago, 2003; Taniguchi et al., 1998) . Furthermore, Kiel, Reitsamer, Walker, and Kiel (2001) reported that systemic NOS inhibition induces ciliary vasoconstriction and decreases production of aqueous humor. NO reactivity is enriched at major sites of outflow resistance, including the trabecular meshwork, Schlemm's canal, and ciliary muscles, and NOS type 3 is the principle NOS isoenzyme found in these areas (Nathanson & McKee, 1995) . Some evidence suggests that NO regulates IOP by inducing relaxation of the ciliary muscle and trabecular meshwork, thereby decreasing the resistance of the outflow pathway (Ding & Abdel-Latif, 1997; Kotikoski, Vapaatalo, & Oksala, 2003; Wiederholt, Sturm, & Lepple-Wienhues, 1994) . The apparent lack of agreement with our results may arise from our use of a different glaucoma model; for example, Giuffrida et al. (2003) used a model in which outflow of the aqueous humor was irreversibly blocked by injection of a-chymotrypsin. In our glaucoma rat model, IOP was unaffected by L-NAME treatment, pos-sibly because L-NAME may affect not only the production of aqueous humor but also the outflow resistance.
In conclusion, the results of this study confirm that retinal levels of nNOS are increased in a glaucoma rat model, as compared to normal rats. This finding lends support to the possibility that excessive NO production may damage RGCs. The increased expression of nNOS in RGCs may provide a clue to the somatic events of glaucomatous optic neuropathy.
